Blood eosinophil count and treatment patterns of chronic obstructive pulmonary disease patients in South Korea using real-world data
The Korean Journal of Internal Medicine · 2025
DOI: 10.3904/kjim.2024.034 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Korean Journal of Internal Medicine, 2025. Verfasst von Chin Kook Rhee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic Unive…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Eosinophils, Registries, Adrenal Cortex Hormones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: GSK R&D Limited.
Themen: COPD
Abstract (Originalsprache)
Background/Aims: Chronic obstructive pulmonary disease (COPD) management guidelines have increasingly emphasised the importance of exacerbation prevention, and the role of blood eosinophil count (BEC) as a biomarker for inhaled corticosteroids (ICS) response. This study aimed to describe the distribution and stability of BEC and understand real-world treatment patterns among COPD patients in South Korea.
Methods
This was a retrospective database analysis using data obtained from the KOrea COPD Subgroup Study (KOCOSS) registry between January 2012 and August 2018. KOCOSS is an ongoing, longitudinal, prospective, multi-centre, non-interventional study investigating early COPD amongst South Korean patients. BEC stability was assessed by calculating the intra-class correlation (ICC) coefficient. “Exacerbators” were patients who had a record of ≥ 1 exacerbation in the 12 months prior to the visit.
Results
The study included 2,661 patients with a mean age of 68.6 years. Most patients were male (92.0%). Mean BEC was significantly higher in exacerbators compared to non-exacerbators. Patients with ≥ 2 exacerbations at baseline had a less stable BEC over time (ICC = 0.44) compared to non-exacerbators (ICC = 0.57). Patients with BEC ≥ 300 cells/μL at baseline predominantly received triple therapy (43.8%).
Conclusions
This study may further develop current understanding on BEC profiles amongst COPD patients in South Korea. BEC measurements are stable and reproducible among COPD patients, which supports its use as a potential biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
- Epidemiology, Health Economics and Strategic Execution, GSK, Singapore.
- Adelphi Real World, Macclesfield, UK.
- Department of Respiratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
Förderung
- GSK R&D Limited
Zitieren
APA
Rhee, C. K., Ho, Y. F., Shantakumar, S., Holbrook, T., Nam, Y., & Yoo, K. H. (2025). Blood eosinophil count and treatment patterns of chronic obstructive pulmonary disease patients in South Korea using real-world data. The Korean Journal of Internal Medicine. https://doi.org/10.3904/kjim.2024.034
Vancouver
Rhee CK, Ho YF, Shantakumar S, Holbrook T, Nam Y, Yoo KH. Blood eosinophil count and treatment patterns of chronic obstructive pulmonary disease patients in South Korea using real-world data. The Korean Journal of Internal Medicine. 2025. doi:10.3904/kjim.2024.034
BibTeX
@article{Rhee2025,
author = {Rhee, Chin Kook and Ho, Yu-Fan and Shantakumar, Sumitra and Holbrook, Tim and Nam, Yein and Yoo, Kwang-Ha},
title = {Blood eosinophil count and treatment patterns of chronic obstructive pulmonary disease patients in South Korea using real-world data},
journal = {The Korean Journal of Internal Medicine},
year = {2025},
doi = {10.3904/kjim.2024.034}
}
EUVIMED